Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Alnylam Pharmaceuticals revenue
Alnylam Pharmaceuticals's revenue is $2.2 billion.
What is Alnylam Pharmaceuticals's revenue?
- Alnylam Pharmaceuticals's revenue growth from 2003 to 2024 is 1,277,310.8%.
- Alnylam Pharmaceuticals has 1,323 employees, and the revenue per employee ratio is $1,699,352.
- Alnylam Pharmaceuticals's peak quarterly revenue was $750.5M in 2023(q3).
- Alnylam Pharmaceuticals peak revenue was $2.2B in 2024.
- Alnylam Pharmaceuticals annual revenue for 2023 was 1.8B, 76.23% growth from 2022.
- Alnylam Pharmaceuticals annual revenue for 2024 was 2.2B, 22.97% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Alnylam Pharmaceuticals historical revenue
Alnylam Pharmaceuticals's peak revenue was $2.2B in 2024. The peak quarterly revenue was $750.5M in 2023(q3).
Alnylam Pharmaceuticals's revenue increased from $176.0k in 2003 to $2.2B currently. That's a 1,277,310.8% change in annual revenue.
Alnylam Pharmaceuticals annual revenue
Alnylam Pharmaceuticals annual revenue over time
| Fiscal year / year | Alnylam Pharmaceuticals revenue |
|---|---|
| 2009 | $100.5M |
| 2010 | $100.0M |
| 2011 | $82.8M |
| 2012 | $66.7M |
| 2013 | $47.2M |
| 2014 | $50.6M |
| 2015 | $41.1M |
| 2016 | $47.2M |
| 2017 | $89.9M |
| 2018 | $74.9M |
| 2019 | $219.8M |
| 2020 | $492.9M |
| 2021 | $844.3M |
| 2022 | $1.0B |
| 2023 | $1.8B |
| 2024 | $2.2B |
Rate Alnylam Pharmaceuticals' financial transparency
Alnylam Pharmaceuticals annual growth
Alnylam Pharmaceuticals saw the greatest revenue growth in 2004, when revenue increased by 2,330.68%.
Alnylam Pharmaceuticals had the lowest revenue growth in 2013, when revenue changed by -29.31%.
Alnylam Pharmaceuticals annual growth rate over time
| Year | Alnylam Pharmaceuticals growth |
|---|---|
| 2009 | 5%↑ |
| 2010 | -0%↓ |
| 2011 | -17%↓ |
| 2012 | -19%↓ |
| 2013 | -29%↓ |
| 2014 | 7%↑ |
| 2015 | -19%↓ |
| 2016 | 15%↑ |
| 2017 | 91%↑ |
| 2018 | -17%↓ |
| 2019 | 193%↑ |
| 2020 | 124%↑ |
| 2021 | 71%↑ |
| 2022 | 23%↑ |
| 2023 | 76%↑ |
| 2024 | 23%↑ |
Alnylam Pharmaceuticals quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Alnylam Pharmaceuticals quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2009 | $25.1M | $24.6M | $24.2M | $26.6M |
| 2010 | $24.6M | $26.6M | $27.7M | $21.2M |
| 2011 | $20.9M | $20.6M | $20.8M | $20.5M |
| 2012 | $20.6M | $20.9M | $16.8M | $8.5M |
| 2013 | $18.6M | $8.7M | $9.0M | $10.8M |
| 2014 | $8.3M | $7.3M | $11.0M | $24.0M |
| 2015 | $18.5M | $8.7M | $6.3M | $7.6M |
| 2016 | $7.3M | $8.7M | $13.7M | $17.5M |
| 2017 | $19.0M | $15.9M | $17.1M | $37.9M |
| 2018 | $21.9M | $29.9M | $2.1M | $21.0M |
| 2019 | $33.3M | $44.7M | $70.1M | $71.7M |
| 2020 | $99.5M | $104.0M | $125.9M | $163.6M |
| 2021 | $177.6M | $220.6M | $187.6M | $258.5M |
| 2022 | $213.3M | $224.8M | $264.3M | $335.0M |
| 2023 | $319.3M | $318.8M | $750.5M | $439.7M |
| 2024 | $494.3M | $659.8M | $500.9M | $593.2M |
Alnylam Pharmaceuticals jobs nearby
Do you work at Alnylam Pharmaceuticals?
Did Alnylam Pharmaceuticals meet its revenue projections?
Alnylam Pharmaceuticals financial information
| CEO | Yvonne L. Greenstreet |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 1,323 |
| Date Founded | 2002 |
| Headquarters | Cambridge, Massachusetts |
| Number of Locations | 2 |
| Revenue | $2.2B |
| Net Income | -$1,131,156,000 |
| Gross Proft | $1.9B (2024) |
| PE Ratio | -29.37 |
| Tax Rate | 0.3% |
| Market Capitalization | $8.2B |
| Total Assets | $3,546,359,000 |
| Ticker | ALNY |
Alnylam Pharmaceuticals jobs you might like
Alnylam Pharmaceuticals financing
Alnylam Pharmaceuticals received early financing of $24.6M on 2003-07-07.
| Series | Round size | Date |
|---|---|---|
| Private Equity | $24.6M | 07/2003 |
| Post Ipo Equity | $10M | 03/2011 |
| Post Ipo Equity | $700M | 01/2014 |
| Post Ipo Equity | $450M | 01/2015 |
| Post Ipo Equity | $800M | 04/2019 |
| Post Ipo Debt | $750M | 04/2020 |
| Post Ipo Equity | $250M | 04/2020 |
Alnylam Pharmaceuticals investors
| Investors | Security type |
|---|---|
| Polaris Partners | Private Equity |
| Abingworth | Private Equity |
| Cardinal Partners | Private Equity |
| Merck & Co. Inc. | Private Equity |
| ARCH Venture Partners | Private Equity |
| Atlas Venture | Private Equity |
| Takeda Pharmaceutical | Post Ipo Equity |
| GENZYME CORP | Post Ipo Equity |
| Regeneron Pharmaceuticals Inc. | Post Ipo Equity |
| Blackstone Credit | Post Ipo Debt |
| Blackstone Life Sciences | Post Ipo Equity |
Alnylam Pharmaceuticals competitors
Alnylam Pharmaceuticals's top competitor, Johnson & Johnson, earned an annual revenue of $88.8B.
Alnylam Pharmaceuticals's smallest competitor is Emisphere Technologies with revenue of $1.2M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Merck | $90,328 | $64.2B | 74,000 | 1,686 |
| Johnson & Johnson | $76,686 | $88.8B | 134,500 | 1,428 |
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 270 |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 645 |
| Regeneron | $85,589 | $14.2B | 9,123 | 379 |
| Forest Laboratories | $91,901 | $3.6B | 6,200 | - |
| Sanofi Genzyme | $84,495 | $4.6B | 12,000 | - |
| Sarepta Therapeutics | $94,985 | $1.9B | 840 | 32 |
| Acorda Therapeutics | $97,279 | $117.6M | 344 | - |
| Ironwood Pharmaceuticals | $93,886 | $351.4M | 219 | 4 |
Alnylam Pharmaceuticals revenue FAQs
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Alnylam Pharmaceuticals highest paying jobs
Zippia gives an in-depth look into the details of Alnylam Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Alnylam Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Alnylam Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Alnylam Pharmaceuticals. The data presented on this page does not represent the view of Alnylam Pharmaceuticals and its employees or that of Zippia.
Alnylam Pharmaceuticals may also be known as or be related to Alnylam Pharmaceuticals, Alnylam Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc. and Alnylam Pharmaceuticals, Inc.